I hereby certify that this is being deposited with the United States Postal

Attorney Docket No.: 019934-000710US Client Reference No.: T019934-000710US

the date indicated above and is address Commissioner for Patents

P.O. Box 1450 Alexandria, VA 22

Service "Express Mail Post Office Address

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GOSLING et al.

Application No.: 09/686,020

Filed: October 10, 2000

For: METHODS OF TREATING A CCX

CKR-MEDIATED DISEASE

(As Amended)

Examiner: Bunner, Bridget E.

Art Unit: 1647

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER

37 CFR §1.97 and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

GOSLING et al.

Application No.: 09/686,020



This IDS is being filed before the mailing date of the final Office Action or

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Scott L. Ausenhus Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: 303-571-4000 Fax: 303-571-4321

SLA:nmb

60043927 v1



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

October 10, 2000 Filing Date First Named Inventor Gosling, Jennifa Art Unit 1647 Examiner Name Bunner, Bridget E.

Complete if Known 09/686,020

(use as many sheets as necessary)

	•	•		• •		Danner, Bridget E.
Shee		1	of	1	Attorney Docket Number	019934-000710US

Application Number

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	C1	GRANT, A. et al. "Hepatic Expression of Secondary Lymphoid Chemokine (CCL21) Promotes the Development of Portal-Associated Lymphoid Tissue in Chronic Inflammatory Liver Disease", <i>Am. J. Pathol.</i> , April 2002, pp. 1445-1455, Vol. 160, no. 4					
	C2	HJELMSTRÖM, P. et al. "Lymphoid Tissue Homing Chemokines are Expressed in Chronic Inflammation", <i>Am. J. Pathol.</i> , April 2000, pp. 1133-1138, Vol. 156, No. 4					
	СЗ	ITAKURA, M. et al. "Blockade of Secondary Lymphoid Tissue Chemokine Exacerbates <i>Propionibacterium acnes</i> -Induced Acute Lung Inflammation", <i>J. Immunol.</i> , 1 Feb 2001, pp. 2071-2079, Vol. 166, No. 3					
	C4	KATOU, F. et al. "Differential expression of CCL19 by DC-Lamp [†] mature dendritic cells in human lymph node versus chronically inflamed skin", <i>J. Pathol.</i> , Jan 2003, pp. 98-106, Vol. 199, no. 1					
	C5	PAPADAKIS, K. et al. "CCR9-Positive Lymphocytes and Thymus-Expressed Chemokine Distinguish Small Bowel from Colonic Crohn's Disease", Gastroenterology, Aug 2001, pp. 246-254, Vol. 121, No. 2					
	C6	WENINGER, W. et al. "Naïve T Cell Recruitment to Nonlymphoid Tissues: A Role for Endothelium-Expressed CC Chemokine Ligand 21 in Autoimmune Disease and Lymphoid Neogenesis", <i>J. Immunol.</i> , 1 May 2003, pp. 4638-4648, Vol. 179, No. 9					
	C7	XANTHOU, G. et al. "'Lymphoid' Chemokine Messenger RNA Expression by Epithelial Cells in the Chronic Inflammatory Lesion of the Salivary Glands of Sjögren's Syndrome Patients", <i>Arthritis Rheum.</i> , Feb 2001, pp. 408-418, Vol. 44, No. 2					

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.